Mirum raises 2026 net product sales outlook to $660-680 million as it targets year-end launch of zilurgisertib

Featured in:
abcd

Mirum Pharmaceuticals (MIRM) Q1 2026 Call Results:

sadasda

Management view

  • “Based on this demand and the continued performance of all brands, we are raising our full-year revenue guidance to $660 million to $680 million.” (CEO and director Christopher Peetz)
  • “IN

Alpha Search Disclaimer: This article was automatically generated by an AI tool from content available on Seeking Alpha and has not been curated or reviewed by humans. Due to the inherent limitations in the apply of AI-based tools, the accuracy, completeness or currency of such articles cannot be guaranteed. This article is for informational purposes only. Seeking Alpha does not take your goals or your financial situation into account and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker-dealer, investment advisor or investment bank in the United States.

abcd
sadasda

Find us on

Latest articles

Related articles

See more articles

Skyworks expects revenue of $900-950 million in the third...

Call Earnings Information: Skyworks Solutions (SWKS) Fiscal Q2 2026 Management view “We delivered a significant victory...

£8,580 invested in Rolls-Royce shares 5 years ago is...

Image source: Getty Images Rolls-Royce holdings...

Pinnacle West expects sales growth of 4-6% in 2026...

Call Earnings Statistics: Pinnacle West (PNW) Q1 2026 Management view “We are off to a solid start...